Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many scientific/mechanistic and safety concepts align with the label excerpt, but the response includes at least two label-incompatible/unverifiable items: one statement explicitly marked absent from the label (practical dosing-timing guidance), and one tablet-strength claim marked absent from the label (5 mg). These limit strict FDA-label adherence.
Category Scores
Accurate Statements
Midodrine is used to treat conditions where blood pressure is too low.
INDICATIONS AND USAGE: indicated for the treatment of symptomatic orthostatic hypotension (OH).
Midodrine is converted in the body into an active form.
CLINICAL PHARMACOLOGY (Mechanism of Action): forms an active metabolite, desglymidodrine.
Midodrine has a vasoconstrictor effect.
CLINICAL PHARMACOLOGY (Mechanism of Action): activation of alpha-adrenergic receptors of arteriolar/venous vasculature producing increase in vascular tone and elevation of blood pressure.
Midodrine helps increase standing blood pressure.
CLINICAL PHARMACOLOGY (Mechanism of Action): rise in standing systolic and diastolic BP after dosing.
Symptomatic orthostatic hypotension is low blood pressure when standing.
CLINICAL PHARMACOLOGY/CLINICAL STUDIES: orthostatic hypotension characterized by supine-to-standing fall in systolic BP with dizziness/lightheadedness.
Common side effects of midodrine can include tingling or scalp tingling.
ADVERSE REACTIONS: paresthesia and pruritus mainly of the scalp; table footnote includes scalp paresthesia.
Common side effects of midodrine can include goosebumps.
ADVERSE REACTIONS: goosebumps; also OVERDOSAGE symptoms include piloerection (goosebumps).
Common side effects of midodrine can include headache.
ADVERSE REACTIONS: less frequent adverse reactions were headache.
The main risk of midodrine is excessive blood pressure elevation when it is not intended (for example, while lying down).
Supine Hypertension/ADVERSE REACTIONS: most potentially serious adverse reaction is marked elevation of supine arterial BP (supine hypertension).
Clinicians often monitor blood pressure patterns and adjust dosing accordingly.
DOSAGE AND ADMINISTRATION: supine and standing BP should be monitored regularly and administration should be stopped if supine BP increases excessively.
Unsupported Statements
Midodrine hydrochloride 5 mg is a tablet strength of midodrine.
The provided label excerpt does not specify a 5 mg tablet strength; evaluation marked 'absent from the label' for this claim.
Common practical guidance for orthostatic hypotension is that doses are taken at times when low blood pressure symptoms are most likely (for example, around periods of standing/activity).
Evaluation marked 'absent from the label'; the excerpt provides daytime/upright scheduling and timing relative to bedtime, not symptom-likelihood/standing-activity timing guidance.
Contradictions
Important Omissions
Label-specific contraindications (e.g., severe organic heart disease, acute renal disease, urinary retention, pheochromocytoma, thyrotoxicosis; persistent and excessive supine hypertension).
Importance:
Moderate
Key label dosing constraints: not later than 6 P.M., not after evening meal, and not less than 4 hours before bedtime; dosing frequency limits; renal caution initiation with 2.5 mg; stopping after initial treatment if significant symptomatic improvement is not reported.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unverifiable/absent-from-label dosing-related practical timing guidance and an unverifiable tablet-strength claim could affect dosing decisions/administration consistency with the label. Other safety statements (supine hypertension risk; monitoring) are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Contains statements marked absent from the label (5 mg tablet-strength claim; symptom-likelihood/standing-activity dosing timing).
Suggested Improvement
Remove or replace absent-from-label claims with label-supported administration guidance (daytime when upright; schedule not later than 6 P.M.; avoid dosing after evening meal or within 4 hours of bedtime; monitor supine/standing BP and stop if supine BP increases excessively).